Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Short term Debt: 2018-2025

  • Dr Reddys Laboratories' Short term Debt rose 190.85% to $445.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $445.0 million, marking a year-over-year increase of 190.85%. This contributed to the annual value of $445.0 million for FY2025, which is 190.85% up from last year.
  • Dr Reddys Laboratories' Short term Debt amounted to $445.0 million in Q1 2025, which was up 190.85% from $153.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' Short term Debt's 5-year high stood at $445.0 million during Q1 2025, with a 5-year trough of $90.0 million in Q1 2023.
  • Moreover, its 3-year median value for Short term Debt was $153.0 million (2024), whereas its average is $229.3 million.
  • Per our database at Business Quant, Dr Reddys Laboratories' Short term Debt slumped by 74.79% in 2023 and then spiked by 190.85% in 2025.
  • Dr Reddys Laboratories' Short term Debt (Quarterly) stood at $316.0 million in 2021, then increased by 12.97% to $357.0 million in 2022, then plummeted by 74.79% to $90.0 million in 2023, then skyrocketed by 70.00% to $153.0 million in 2024, then spiked by 190.85% to $445.0 million in 2025.
  • Its last three reported values are $445.0 million in Q1 2025, $153.0 million for Q1 2024, and $90.0 million during Q1 2023.